IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v48y2025i2d10.1007_s40264-024-01489-3.html
   My bibliography  Save this article

Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study

Author

Listed:
  • Eyob Alemayehu Gebreyohannes

    (UniSA Clinical and Health Sciences, University of South Australia
    The University of Western Australia)

  • Christopher Thornton

    (University of South Australia)

  • Myra Thiessen

    (Monash University)

  • Sieta T. Vries

    (University Medical Center Groningen)

  • Gretchen Coombs

    (Monash University)

  • Indae Hwang

    (Monash University)

  • Renly Lim

    (UniSA Clinical and Health Sciences, University of South Australia)

Abstract

Background Reporting of adverse drug events (ADEs) to regulatory authorities remains low, particularly among consumers. Objectives To explore stakeholders’ views on the development and use of a digital platform to improve ADE reporting by consumers to the regulatory authority in Australia, i.e., the Therapeutic Goods Administration. Methods A qualitative study was conducted using semi-structured interviews, focus group discussions (FGDs), and co-design workshops with consumers, healthcare professionals (HCPs), and regulators. The interview recordings were transcribed verbatim, coded, and analysed thematically according to the Capability, Opportunity, Motivation, Behaviour model. Findings of the FGDs and co-design workshops were incorporated to enhance and complement the insights gathered from the interviews. Results A total of 39 participants took part in the study (54 % consumers, 41 % HCPs, and 5 % regulators). Uncovered themes related to ADE reporting in general were: difficulty recognizing ADEs and health literacy, awareness about reporting ADEs (Capability); visibility of ADE reporting, professionals’ views on consumer ADE reporting, consumer education (Opportunity); the common good, benefit to the reporter, identifying ADEs worth reporting, and concern about reporting (Motivation). Additional identified themes specific to a new digital platform were: physical abilities (Capability); features that facilitate intuitive use, convenience and accessibility, user experience, integration with existing systems, trust, sharing experiences with others (Opportunity); and concern about using a reporting platform, and feedback loop (Motivation). Conclusions A cross-section of attitudes and values were obtained regarding ADE reporting in general and a new ADE reporting digital platform for consumers in Australia, which will inform its development, implementation and evaluation.

Suggested Citation

  • Eyob Alemayehu Gebreyohannes & Christopher Thornton & Myra Thiessen & Sieta T. Vries & Gretchen Coombs & Indae Hwang & Renly Lim, 2025. "Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study," Drug Safety, Springer, vol. 48(2), pages 179-190, February.
    • Handle: RePEc:spr:drugsa:v:48:y:2025:i:2:d:10.1007_s40264-024-01489-3
    DOI: 10.1007/s40264-024-01489-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-024-01489-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-024-01489-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Cristiano Matos & Linda Härmark & Florence Hunsel, 2016. "Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs," Drug Safety, Springer, vol. 39(11), pages 1105-1116, November.
    2. Sieta T. Vries & Lisa Wong & Alastair Sutcliffe & François Houÿez & Carmen Lasheras Ruiz & Peter G. M. Mol, 2017. "Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study," Drug Safety, Springer, vol. 40(5), pages 443-455, May.
    3. Carrie E. Pierce & Sieta T. Vries & Stephanie Bodin-Parssinen & Linda Härmark & Phil Tregunno & David J. Lewis & Simon Maskell & Raphael Eemeren & Alicia Ptaszynska-Neophytou & Victoria Newbould & Nab, 2019. "Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR," Drug Safety, Springer, vol. 42(4), pages 477-489, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joanne Barnes & Jane L. Sheridan & Christine Yang Dong & Linda Härmark & Sunita Vohra & Mira Harrison-Woolrych, 2020. "Evaluation of a Web-Based, ‘Purchase Event’ Intensive Monitoring Method for Pharmacovigilance of Natural Health Products: Lessons and Insights from Development Work in New Zealand," Drug Safety, Springer, vol. 43(10), pages 981-998, October.
    2. Sieta T. de Vries & Judy Harrison & Patrick Revelle & Alicia Ptaszynska-Neophytou & Anna Radecka & Gowthamei Ragunathan & Phil Tregunno & Petra Denig & Peter G. M. Mol, 2019. "Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study," Drug Safety, Springer, vol. 42(7), pages 881-886, July.
    3. George Tsey Sabblah & Delese Mimi Darko & Hudu Mogtari & Linda Härmark & Eugène Puijenbroek, 2017. "Patients’ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana," Drug Safety, Springer, vol. 40(10), pages 911-921, October.
    4. Sieta T. de Vries & Petra Denig & Carmen Lasheras Ruiz & François Houÿez & Lisa Wong & Alastair Sutcliffe & Peter G. M. Mol, 2018. "Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients," Drug Safety, Springer, vol. 41(7), pages 697-712, July.
    5. Babafunso Aderemi Adenuga & Timothy William Rennie, 2019. "A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia," Drug Safety, Springer, vol. 42(7), pages 915-917, July.
    6. Christine Mary Hallinan & Yvonne Ann Bonomo, 2022. "The Rise and Rise of Medicinal Cannabis, What Now? Medicinal Cannabis Prescribing in Australia 2017–2022," IJERPH, MDPI, vol. 19(16), pages 1-7, August.
    7. Inácio, Pedro & Gomes, João José & Airaksinen, Marja & Cavaco, Afonso, 2018. "Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients," Health Policy, Elsevier, vol. 122(3), pages 263-268.
    8. Cristiano Matos & Gerda Weits & Florence Hunsel, 2019. "The Role of European Patient Organizations in Pharmacovigilance," Drug Safety, Springer, vol. 42(4), pages 547-557, April.
    9. Katherine Chinchilla & Cristiano Matos & Victoria Hall & Florence Hunsel, 2021. "Patient Organizations’ Barriers in Pharmacovigilance and Strategies to Stimulate Their Participation," Drug Safety, Springer, vol. 44(2), pages 181-191, February.
    10. Patrick Christ & Diana Dubrall & Matthias Schmid & Bernhardt Sachs, 2023. "Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers," Drug Safety, Springer, vol. 46(12), pages 1363-1379, December.
    11. Ronald Kiguba & Henry Zakumumpa & Helen B. Ndagije & Norah Mwebaza & Ronald Ssenyonga & Phil Tregunno & Kendal Harrison & Munir Pirmohamed, 2023. "Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study," Drug Safety, Springer, vol. 46(6), pages 565-574, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:48:y:2025:i:2:d:10.1007_s40264-024-01489-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.